Daix (France), 25 April 2023



Dear shareholder,

I am pleased to invite you to Inventiva's next shareholder meeting, which will take place in-person on May 25<sup>th</sup>, 2023, at Hotel Océania Le Jura, 14 avenue Foch – 21000 Dijon, France.

I would like to take this opportunity to review the progress we made in 2022 in our clinical programmes and financial position, in a market context that particularly affected biotechnology companies.

We kept on executing our roadmap despite a challenging environment and continued to make significant progress in the development of lanifibranor, our lead drug candidate for the treatment of patients with non-alcoholic steatohepatitis (NASH). NASH is a severe, untreated liver disease that affects approximately 6%<sup>1</sup> of the adult population in the United States. There are no approved treatments to date and lanifibranor is one of the most advanced compounds in this very promising market. In September 2022, we entered into a major partnership with Sino Biopharm to develop and commercialise lanifibranor in mainland China, Hong Kong, Macao and Taiwan. This partnership gives us access to a highly attractive market and makes us eligible to receive up to \$290 million in milestone payments in addition to tiered royalties on net sales of lanifibranor in China, subject to regulatory approval. We also initiated a Phase II combination trial with lanifibranor and empagliflozin in the U.S. in July 2022. This study aims to demonstrate that the combination of lanifibranor with empagliflozin, a type 2 diabetes drug with sales of \$5.8 billion in 2022<sup>2</sup>, improves glycated haemoglobin levels.

Recently, we made significant changes to our Phase III NATiV3 study to bring us in line with the most up-to-date industry practice. We now have a more attractive study for patients and investigators. Throughout the year we continued to roll out this pivotal study, and it is a great source of pride to know that more than 350 clinical sites in 23 countries around the world are participating in this study. Finally, we also strengthened our patent portfolio and extended the protection of lanifibranor in the U.S. in patients with cirrhotic NASH.

In parallel with this progress, we strengthened our financial position during the year. We entered into a credit agreement of up to  $\leq$ 50 million with the European Investment Bank, one of the largest ever granted by the institution to a biotech company in France, of which we drew down the first  $\leq$ 25 million tranche in December 2022. In July 2022, we raised nearly  $\leq$ 15 million, including more than  $\leq$ 9 million (gross proceeds) through our *At-The-Market (ATM)* equity financing programme in the U.S., and  $\leq$ 5.3 million in loan agreements with a syndicate of French banks. Finally, as part of our collaboration with Sino Biopharm, we received an upfront payment of  $\leq$ 12.8 million in November 2022.

In addition, Inventiva, which operates in the field of human health innovation, is fully aware of the global challenges of CSR<sup>3</sup>. The level of attention and reporting<sup>4</sup> on non-financial management information was already voluntarily maintained despite the regulatory changes in 2019 and 2020 on these sustainability issues. In 2022, the Company has decided to strengthen its action on these issues and has initiated its

<sup>&</sup>lt;sup>1</sup> Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73–84

<sup>&</sup>lt;sup>2</sup> Boehringer Ingelheim Annual 2022 Report

<sup>&</sup>lt;sup>3</sup> CSR: Corporate Social Responsibility

<sup>&</sup>lt;sup>4</sup> Cf. URD 2022 chapter 5 « Déclaration de Performances Extra Financière » (DPEF)

CSR approach by following the guidelines of ISO 26000, one of the generally accepted global approaches in this field.

All these achievements are the results of our collective effort and daily commitment of our teams. I am pleased to share these achievements with you and we look forward to the next developments in 2023: results from our Phase II clinical study evaluating lanifibranor for the treatment of NAFLD (Non Alcoholic Fatty Liver Disease) in patients with type 2 diabetes, results from our Phase IIa LEGEND study combining lanifibranor and empagliflozin in patients with NASH and type 2 diabetes, as well as the completion of patient enrolment in our Phase III clinical study NATiV3.

I would like to take this opportunity to thank you once again for your confidence in Inventiva.

Yours sincerely,

Frédéric Cren Chief Executive Officer and cofounder of Inventiva

### INVENTIVA

French *société anonyme* with a Board of Directors With a share capital of EUR 421,341.69 Registerd office: 50, Rue de Dijon, 21121 Daix, France 537 530 255 Trade and Companies Registry of Dijon

### ORDINARY AND EXTRAORDINARY GENERAL MEETING OF MAY 25<sup>TH</sup>, 2023

The shareholders of the company INVENTIVA (the "**Company**") are hereby informed that the Ordinary and Extraordinary General Meeting is to be held on May 25<sup>th</sup>, 2023 at 2:00 p.m. at: Hôtel Oceania Le Jura – 14 avenue Foch - 21000 Dijon, France, as mentioned in the prior notice of meeting published in the *Bulletin des Annonces Légales et Obligatoires* (BALO) n°46 dated April 17<sup>th</sup>, 2023.

The General Meeting is convened to deliberate on the following agenda:

### <u>Agenda</u>

Reading of the reports of the Board of Directors and the Auditors;

#### On an ordinary basis

- 1. Approval of the statutory financial statements for the financial year ended December 31<sup>st</sup>, 2022;
- 2. Approval of the consolidated financial statements for the financial year ended December 31<sup>st</sup>, 2022;
- 3. Appropriation of profit/loss for the financial year ended December 31<sup>st</sup>, 2022;
- 4. Approval of the expenses and charges referred to in Article 39(4) of the French General Tax Code;
- 5. Related-party agreements;
- Final approval of the fixed and variable compensation paid or awarded to Mr. Frédéric Cren in his capacity as Chairman of the Board of Directors and Chief Executive Officer for the financial year ended December 31<sup>st</sup>, 2022;
- 7. Final approval of the fixed and variable compensation paid or awarded to Mr. Pierre Broqua in his capacity as Deputy Chief Executive Officer for the financial year ended December 31<sup>st</sup>, 2022;
- 8. Approval of the information on corporate officers' compensation included in the corporate governance report and referred to in Article L.22-10-9 I. of the French Commercial Code;
- 9. Approval of the compensation policy for Mr. Frédéric Cren in his capacity as Chairman of the Board of Directors and Chief Executive Officer;
- 10. Approval of the compensation policy for Mr. Pierre Broqua in his capacity as Deputy Chief Executive Officer;
- 11. Approval of the compensation policy of the Company's directors;
- 12. Authorization granted to the Board of Directors to buyback the Company's shares;

### On an extraordinary basis

13. Authorization to the Board of Directors to reduce the share capital by cancellation of shares;

#### On an ordinary basis

14. Power for formalities.

#### DRAFT TEXT OF RESOLUTIONS <u>TO BE SUBMITTED TO THE VOTE</u> OF THE ORDINARY AND EXTRAORDINARY GENERAL MEETING OF MAY 25<sup>TH</sup>, 2023

#### **ORDINARY RESOLUTIONS**

**FIRST RESOLUTION** (Approval of the statutory financial statements for the financial year ended December 31<sup>st</sup>, 2022)

The General Meeting, deliberating in accordance with the quorum and majority requirements for ordinary general meetings, having acquainted itself with the Board of Directors' management report and the Statutory Auditors' general report on the annual statutory financial statements,

**Approves** the financial statements for the financial year ended December 31<sup>st</sup>, 2022 as presented, including the balance sheet, income statement and appendix to the financial statements, as well as the transactions reflected in these financial statements and summarized in these reports, showing a net accounting loss of EUR 64,467,085.51.

**SECOND RESOLUTION** (Approval of the consolidated financial statements for the financial year ended December 31<sup>st</sup>, 2022)

The General Meeting, deliberating in accordance with the quorum and majority requirements for ordinary general meetings, having acquainted itself with the Board of Directors' management report and the Statutory Auditors' general report on the consolidated financial statements,

**Approves** the consolidated financial statements for the financial year ended December 31<sup>st</sup>, 2022 as presented, as well as the transactions reflected in these accounts or summarized in these reports.

#### *THIRD RESOLUTION* (*Appropriation of profit/loss for the financial year ended December 31st, 2022*)

The General Meeting, deliberating in accordance with the quorum and majority requirements for ordinary general meetings, having acquainted itself with the management report of the Board of Directors, as well as the general report of the Statutory Auditors,

Having recorded that the annual financial statements showed a net accounting loss of EUR 64,467,085.51,

**Resolves** to wholly allocate this net accounting loss of EUR 64,467,085.51 to the "*Report à Nouveau*" account, bringing its debit amount to EUR 143,729,006.95.

Notes that no dividend has been distributed since the Company's incorporation.

# **FOURTH RESOLUTION** (Approval of the expenses and charges referred to in Article 39(4) of the French General Tax Code)

The General Meeting, deliberating in accordance with the quorum and majority requirements for ordinary general meetings, having acquainted itself with the management report of the Board of Directors, as well as the general report of the Statutory Auditors, acting in accordance with the provisions of Article 223 quater of the French General Tax Code,

**Approves** the non-deductible expenses and charges for tax purposes, referred to in Article 39, paragraph 4 of the said Code, which amount to EUR 10,217 for the financial year 2022, and acknowledges the absence of corporate income tax borne in respect of these expenses and charges in view of the loss for said financial year.

# FIFTH RESOLUTION (Related-party agreements)

The General Meeting, deliberating in accordance with the quorum and majority requirements for ordinary general meetings, having acquainted itself with the special report of the Statutory Auditors on related-party agreements referred to in Article L.225-38 seq. of the French Commercial Code,

Approves this report and acknowledges prior such agreements which performance has been pursed during the financial year ended December 31<sup>st</sup>, 2022.

*SIXTH RESOLUTION* (Final approval of the fixed and variable compensation paid or awarded to Mr. Frédéric Cren in his capacity as Chairman of the Board of Directors and Chief Executive Officer for the financial year ended December 31<sup>st</sup>, 2022)

The General Meeting, deliberating in accordance with the quorum and majority requirements for ordinary general meetings, having acquainted itself with the report on corporate governance referred to in Article L.225-37 of the French Commercial Code,

**Approves**, pursuant to article L.22-10-34 II. of the French Commercial Code, the fixed, variable and exceptional elements composing the total compensation and benefits of any kind paid during the previous fiscal year or awarded in respect of the same financial year to Mr. Frédéric Cren in his capacity as Chairman of the Board of Directors and Chief Executive Officer, contained therein, as presented in the universal registration document including the 2022 Annual Financial Report, Part 3, Section 3.5.1.5.

**SEVENTH RESOLUTION** (Final approval of the fixed and variable compensation paid or awarded to Mr. Pierre Broqua in his capacity as Deputy Chief Executive Officer for the financial year ended December 31<sup>st</sup>, 2022)

The General Meeting, deliberating in accordance with the quorum and majority requirements for ordinary general meetings, having acquainted itself with the report on corporate governance referred to in Article L.225-37 of the French Commercial Code,

**Approves**, pursuant to article L.22-10-34 II. of the French Commercial Code, the fixed, variable and exceptional elements composing the total compensation and benefits of any kind paid during the previous fiscal year or awarded in respect of the same financial year to Mr. Pierre Broqua in his capacity as Deputy Chief Executive Officer, contained therein, as presented in the universal registration document including the 2022 Annual Financial Report, Part 3, Section 3.5.1.5.

**EIGHTH RESOLUTION** (Approval of the information on corporate officers' compensation included in the corporate governance report and referred to in Article L.22-10-9 I. of the French Commercial Code)

The General Meeting, deliberating in accordance with the quorum and majority requirements for ordinary general meetings, having acquainted itself with the report on corporate governance referred to in Article L.225-37 of the French Commercial Code,

**Approves**, pursuant to article L.22-10-34 I. of the French Commercial Code, the information mentioned in Article L22-10-9 I. of the French Commercial Code, contained therein, as presented in the universal registration document including the 2022 Annual Financial Report, Part 3, Section 3.5.1.6.

**NINETH RESOLUTION** (Approval of the compensation policy for Mr. Frédéric Cren in his capacity as Chairman of the Board of Directors and Chief Executive Officer)

The General Meeting, deliberating in accordance with the quorum and majority requirements for ordinary general meetings, having acquainted itself with the report on corporate governance referred to in Article L.225-37 of the French Commercial Code describing the components of the compensation policy of corporate officers,

**Approves**, pursuant to article L.22-10-8 II. of the French Commercial Code, the compensation policy of the Chairman of the Board of Directors and Chief Executive Officer, Mr. Frédéric Cren, including the policy common

to all corporate officers and the provisions specific to him, contained therein, as presented in the universal registration document including the 2022 Annual Financial Report, Part 3, Sections 3.5.1.1 and 3.5.1.2.

**TENTH RESOLUTION** Approval of the compensation policy for Mr. Pierre Broqua in his capacity as Deputy Chief Executive Officer)

The General Meeting, deliberating in accordance with the quorum and majority requirements for ordinary general meetings, having acquainted itself with the report on corporate governance referred to in Article L.225-37 of the French Commercial Code describing the components of the compensation policy of corporate officers,

**Approves**, pursuant to article L.22-10-8 II. of the French Commercial Code, the compensation policy of the Deputy Chief Executive Offier, Mr. Pierre Broqua, including the policy common to all corporate officers and the provisions specific to him, contained therein, as presented in the universal registration document including the 2022 Annual Financial Report, Part 3, Section 3.5.1.1 and 3.5.1.2.

### **ELEVENTH RESOLUTION** (Approval of the compensation policy of the Company's Directors)

The General Meeting, deliberating in accordance with the quorum and majority requirements for ordinary general meetings, having acquainted itself with the report on corporate governance referred to in Article L.225-37 of the French Commercial Code describing the components of the compensation policy of corporate officers,

**Approves**, pursuant to article L.22-10-8 II. of the French Commercial Code, the compensation policy of the Directors, including the policy common to all corporate officers and the provisions specific to them, contained therein, as presented in the universal registration document including the 2022 Annual Financial Report, Part 3, Section 3.5.1.3.

### **TWELFTH RESOLUTION** (Authorization granted to the Board of Directors to buyback the Company's shares)

The General Meeting, deliberating in accordance with the quorum and majority requirements for ordinary general meetings, having acquainted itself with the Board of Directors' report,

**1.** Authorizes the Board of Directors, with the faculty to sub-delegate under the conditions provided for by law and for a period of eighteen months from this day, in accordance with the provisions of Articles L.22-10-62 seq. of the French Commercial Code, Articles 241-1 to 241-5 of the General Regulations of the *Autorité des marchés financiers* (AMF), and the European regulations applicable to market abuse and market practices permitted by the AMF, to purchase, on one or more occasions and at the times it shall determine, a number of ordinary shares of the Company not to exceed 10% of the total number of shares comprising the share capital at any time.

This percentage applies to a number of shares adjusted, if necessary, to reflect transactions that may affect the share capital subsequent to this Meeting, and when shares are purchased to promote liquidity under the conditions defined by the General Regulations of the AMF, the number of shares taken into account for the calculation of the aforementioned 10% limit corresponds to the number of shares purchased, less the number of shares resold during the authorization period.

Under no circumstances may the Company hold more than 10% of the shares comprising its share capital at any time as a result of acquisitions made by the Company.

2. Resolves that the buyback of these ordinary shares can be carried out in order:

- to implement and perform obligations related to stock option programs or other share allocations to employees and corporate officers of the Company and, in particular, to allocate shares to employees and corporate officers of the Company in connection with (i) profit-sharing, or (ii) any share purchase, stock option or free share allocation plan under the conditions provided for by law, in particular by Articles L.3331-1 seq. of the French Labor Code (including any sale of shares referred to in Article L.3332-24 of the French Labor Code), and to carry out any hedging transactions relating to such transactions;
- to purchase or sell shares under a liquidity agreement entered into with an investment services provider, in accordance with the conditions set by the market authorities;
- to deliver ordinary shares upon the exercise of rights attached to securities carrying rights to shares of the

Company by redemption, conversion, exchange, presentation of a warrant or any other means;

- to reduce the Company's capital by cancelling all or some of the shares acquired; and
- more generally, to carry out any transaction that may be authorized by law or any market practice that may be admitted by the market authorities, it being specified that, in such a case, the Company would inform its shareholders by means of a press release.

**3. Resolves** that the maximum unit purchase price may not exceed, excluding charges, forty euros ( $\notin$  40) (or the equivalent value of this amount on the same date in any other currency). The Board of Directors may, however, in the event of transactions affecting the Company's share capital, in particular a change in the par value of the ordinary share, a capital increase by incorporation of reserves followed by the creation and allocation of free shares, a stock split or reverse stock split, distribution of reserves or any other assets, amortization of capital or any other transaction affecting shareholders' equity, adjust the aforementioned maximum purchase price to take into account the impact of such transactions on the value of the share.

**4. Resolves** that the purchase, sale or transfer of these shares may be carried out and paid for by any means authorized by current or future regulations, on a regulated market, on a multilateral trading facility, with a systematic internalizer or on an electronic communications network, in particular through the purchase or sale of blocks of shares, through the use of options or other forward financial instruments or forward contracts, or through the use of warrants or, more generally, of securities carrying rights to shares of the Company, at the times the Board of Directors shall determine.

**5. Resolves** that the Board of Directors shall have full powers, with the option to sub-delegate such powers, to carry out, in compliance with the relevant legal and regulatory provisions, the permitted reallocation of shares purchased for one of the objectives of the program to one or more of its other objectives, or to sell them, whether on or off-market.

**6. Resolves** that the Board of Directors shall have full powers, with the option to sub-delegate such powers, to decide and implement this authorization and to determine the terms and conditions thereof in accordance with the law and this resolution, and in particular to place any and all stock market orders, enter into any and all agreements, in particular for the keeping of registers of purchases and sales of shares, make any and all declarations to the AMF or any other authority, draw up any and all documents, in particular information documents, complete any and all formalities, and generally do whatever is necessary.

**7. Acknowledges** that the Board of Directors shall inform the Ordinary General Meeting of the transactions carried out under this authorization, as required by law.

**8. Resolves** that this authorization, as from its use by the Board of Directors, cancels and replaces, for the remaining period and unused amounts, the authorization granted to the Board of Directors by the Combined General Meeting of May 19<sup>th</sup>, 2022, in its nineteenth (19<sup>th</sup>) resolution.

### EXTRAORDINARY RESOLUTIONS

**THIRTEENTH RESOLUTION** (Authorization to the Board of Directors to reduce the share capital by cancellation of shares)

The General Meeting, voting under the rules of quorum and majority required for extraordinary general meetings, having reviewed the Board of Directors' Report and the Statutory Auditors' special report and acting pursuant to the provisions of Article L.22-10-62 of the French Commercial Code,

1. Authorize the Board of Directors to cancel, in the proportions and at the times it deems fit, in one or more times, all or part of the ordinary shares acquired by the Company and/or which it may acquire in the future under any authorization given by the Ordinary General Meeting pursuant to Article L. 22-10-62 of the French Commercial Code, up to a limit of 10% of the Company's share capital per 24-month period, it being recalled that this 10% limit applies to a number of shares adjusted, if necessary, according to the transactions that may affect the share capital after this Meeting.

**2. Decides** that the excess of the purchase price of the ordinary shares over their nominal value will be charged to the "share premium" account or to any available reserve account, including the legal reserve, up to a limit of 10% of the capital reduction carried out.

**3.** Authorize the Board of Directors to reduce the share capital accordingly.

**4. Decides** that the Board of Directors will have full authority, with the right to sub-delegate under the conditions provided by French law, to implement this resolution and in particular :

- determine the final amount of such capital reduction, set the terms and conditions thereof and record the completion thereof;
- charge the difference between the carrying amount of the cancelled ordinary shares and their nominal amount to all available reserves and premiums, including the legal reserve, up to a maximum of 10% of the cancelled capital;
- amend the bylaws accordingly; and
- carry out all formalities (in particular with the AMF), take all steps and make all declarations to all institutions and, in general, do all that is necessary.

**5. Decides** that the aforementioned delegation is granted for a period of 18 months as from the date of this General Meeting and terminates, with immediate effect, any previous delegation granted for the same purpose. It therefore supersedes the delegation granted by the Combined General Meeting dated May 19<sup>th</sup>, 2022 in its twentieth (20<sup>th</sup>) resolution.

# **ORDINARY RESOLUTION**

### FOURTEENTH RESOLUTION (Power for formalities)

The General Meeting, deliberating in accordance with the quorum and majority requirements for ordinary general meetings,

**Grants** full powers to the bearer of an original, copy or extract of the minutes of this General Meeting to carry out all publication and filing formalities, and generally to do whatever is necessary.

### INFORMATION

### Shareholder status

Pursuant to Article R. 22-10-28 of the French Commercial Code, will be able to participate in the General Meeting, the shareholders who will justify:

- In the case of registered shares: of an account registration of said shares in the Company's registered share accounts by Tuesday, May 23<sup>rd</sup>, 2023, zero hour, Paris time;
- In the case of bearer shares: of an account registration of said shares (if applicable, in the name of the intermediary registered on behalf of the shareholder concerned in accordance with the legal and regulatory requirements) in the bearer securities accounts held by their intermediary by Tuesday, May 23<sup>rd</sup>, 2023, zero hour, Paris time. The authorized intermediaries will deliver a certificate of securities ownership, as an appendix to the remote voting form or proxy form filled by the shareholder or on behalf of the shareholder represented by the registered intermediary.

Only those shareholders who can prove their status by or before Tuesday, May 23<sup>rd</sup>, 2023, zero hour, Paris time, under the conditions set out above, will be able to participate in this General Meeting.

# Method of participation in the General Meeting

Shareholders have several options for participating in the General Meeting. They can (1) vote while physically attending the General Meeting or (2) vote remotely or by proxy (a) by mail or (b) via Internet.

Pursuant to the provisions of Article R. 22-10-28, III, of the French Commercial Code, once a shareholder votes remotely, sends a proxy or asks for an admission card or a certificate to participate in the General Meeting, he or she will not be able to choose another method of participation.

# 1. Vote by physically attending the General Meeting

The shareholders wishing to personally attend the General Meeting must request an admission card as soon as possible to receive the card in a timely manner:

- For registered shareholders: either by returning the single form duly completed and signed using the prepaid reply envelope enclosed with the invitation received by post mail; or by logging in on the website www.sharinbox.societegenerale.com using their usual access codes or their login email (if they have already activated their Sharinbox by SG Markets account), together with the password they already have. The password to connect to the site was sent to them by post when they first contacted Société Générale Securities Services. It can be re-sent by clicking on "Obtain your codes" on the home page of the website. Once connected, they should follow the procedure described on the screen to access the VOTACCESS platform and request their admission card; the registered shareholder who would not have received her admission card may spontaneously attend the General Meeting with an identification document.
- <u>For holders of bearer shares</u>: either by asking the authorized intermediary managing their share-accounts to send them an admission card. Should the admission card not be received by May 23<sup>rd</sup>, 2023, zero hour, Paris time, the shareholder shall ask the authorized intermediary managing their share-accounts to issue a certificate of participation in order to prove their status as shareholders; or by logging in on the Internet portal of their account holder with their usual access codes. The shareholder will then have to click on the icon that will appear on the line corresponding to their Inventiva shares to access the Votaccess website and follow the procedure described on the screen. Only the bearer shareholder whose account holder has subscribed to the Votaccess website will be able to fulfil their request for admission card via Internet.

On the day of the General Meeting, each shareholder will have to prove her quality during the registration process.

### 2. Vote remotely or by proxy

The shareholders not physically attending the General Meeting will be able to vote remotely or to give proxy to the President of the General Meeting, to their spouse, to their partner with whom a *pacte civil de solidarité* has

been made, to another shareholder or to any other individual or legal entity of their choosing, subject to the conditions set forth in Articles L. 225-106 and L. 22-10-30 of the French Commercial Code.

Pursuant to the provisions of Article R. 225-79 of the French Commercial Code, the proxy given by a shareholder to be represented must be signed by the shareholder. The proxy will specify his/her last name, first name and address, and will designate a proxy, including his/her last name, first name and address or for a legal entity, its corporate name and registered office. The proxy does not have the right delegate its duties to another individual or legal entity.

It is specified that, for any proxy without indication of an agent, the President of the General Meeting will vote in favor of adopting the draft resolutions presented or approved to by the Board of Directors and vote against adopting all other draft resolutions. To vote otherwise, the shareholders will have to designate an agent who will accept to vote as provided by the principal.

a. To vote remotely or by proxy by mail:

<u>For registered shareholders</u>: a postal voting form or proxy form will be sent directly to them. This form should be returned in the prepaid T envelope enclosed with the notice of meeting.

<u>For holders of bearer shares</u>: from this day, the postal voting form or proxy form can be requested from the intermediaries managing their shares. Each demand must be addressed by the financial intermediary to the *Services des Assemblées* of Société Générale, 32, rue du Champs de Tir, CS 30812, 44308 Nantes Cedex 3 at the latest six days before the date of the General Meeting (Article R. 225-75 of the French Commercial Code). The single postal voting form or proxy form must be submitted with a certificate of securities ownership drawn up by the financial intermediary who will have to forward these documents to the *Services des Assemblées* of Société Générale, 32, rue du Champs de Tir, CS 30812, 44308 Nantes Cedex 3.

In any case, the postal voting form or proxy voting form duly filled and signed (and accompanied by the certificate of securities ownership for the bearer shares) must be returned in such a way that the *Services des Assemblées* of Société Générale or the Company can receive it at least 3 days before the date of the General Meeting (that is Monday, May 22<sup>th</sup>, 2023).

### b. To vote or give proxy via Internet

Shareholders also have the option of transmitting their voting instructions and giving or revoking a proxy via Internet before the General Meeting, on the website Votaccess, under the following conditions:

For registered shareholders: their usual access codes or their login email (if they have already activated their Sharinbox by SG Markets account), together with the password they already have. The password to connect to the site was sent to them by post when they first contacted Société Générale Securities Services. It can be re-sent by clicking on "Obtain your codes" on the home page of the website. Once connected, they should follow the procedure described on the screen to access the VOTACCESS platform;

they also may give or revoke a proxy by sending an e-mail with an electronic signature, obtained by them from a third party certifier duly authorized pursuant to legal and regulatory provisions in force, to the electronic address Agiva25052023@inventivapharma.com specifying, as for pure registered shareholders, their name, first name, address and their Société Générale access code (information available at the top left of their account statement), or, as for administered registered shareholders, their access code with their authorized intermediary, as well as the name, first name and address of the appointed or revoked agent;

For any request, SGSS is available to shareholders from 9:30 a.m. to 6:00 p.m. on the following telephone number: + 33 (0)2 51 85 67 89;

- <u>For holders of bearer shares</u>: they will have to log in on the Internet portal of their account holders with their usual access codes. They will then have to click on the icon that will appear on the line corresponding to their Inventiva shares to access the Votaccess website and follow the procedure described on the screen.

Beware, only those shareholders whose account holder has subscribed to Votaccess will be able to vote, give or revoke a proxy via Internet.

If the account holder of the shareholder has not subscribed to Votaccess, the notice of appointment and revocation of a proxy can nevertheless be effectuated by electronic means in accordance with the provisions of Articles R. 22-10-24 and R. 225-79 of the French Commercial Code according to the following procedures: by sending an e-mail with an electronic signature, obtained by them from a third party certifier duly authorized pursuant to legal and regulatory provisions in force, to the electronic address Agiva25052023@inventivapharma.com specifying their last name, first name, address, and their share-account's full bank references, as well as the last name, first name and address of the appointed or revoked agent, and then by asking imperatively to the authorized intermediary managing their share-accounts to send a written confirmation to the *Services des Assemblées* of Société Générale.

In order for the duly signed and completed appointments or revocations of proxy notified electronically to be validly taken into account, they must reach the Company no later than Monday, May 22<sup>th</sup>, 2023.

The revocation of a proxy is carried out under the same conditions of form as those used for its appointment.

The secured platform Votaccess will be open as of Friday, May 5<sup>th</sup>, 2023, 9 a.m., Paris time. The ability to vote, give or revoke a proxy via Internet prior to the General Meeting will end on Wednesday, May 24<sup>th</sup>, 2023, 3 p.m., Paris time. Shareholders are advised not to wait until the last days before the General Meeting to enter their instructions.

You are reminded that, in accordance with the provisions of Article R. 22-10-28 of the French Commercial Code:

- Any shareholder who has carried out any of the above formalities may sell all or part of his shares. However, if the sale is carried out before the second (2<sup>nd</sup>) business day preceding the General Meeting at zero hour, Paris time, that is Tuesday, May 23<sup>rd</sup>, 2023 the Company or its proxy cancels or modifies accordingly, depending on the case, the vote or proxy. To this end, the authorized intermediary holding the account notifies the Company or its authorized representative of the transfer and provides it with the necessary information;
- If the sale occurs after this period, it does not have to be notified by the authorized intermediary or taken into consideration by the Company, notwithstanding any agreement to the contrary.

#### Submission of written questions

In accordance with the provisions of Article R. 225-84 of the French Commercial Code, each shareholder will have the right to submit written questions to the Board of Directors no later than the fourth (4<sup>th</sup>) business day preceding the date of the General Meeting, i.e. Friday, May 19<sup>th</sup>, 2023.

Requests for submissions of written questions must be sent to the Company's registered office by registered letter with acknowledgement of receipt. They must be accompanied by a certificate of account registration.

### **Right of communication**

All the documents and information provided for in Article R. 22-10-23 of the French Commercial Code (in particular the text of the draft resolutions presented to the General Meeting by the Board of Directors) can be consulted on the Company's website (www.Inventivapharma.com) as of the twenty first day preceding the meeting, that is Thursday, May 4<sup>th</sup>, 2023.

All the documents referred to in Articles R. 225-89 seq. of the French Commercial Code will be made available to shareholders at the Company's registered office as of the publication of the notice of meeting or on the fifteenth day preceding the General Meeting at the latest, depending on the document concerned.

As from the notice of meeting, shareholders may ask the Company to send them the documents and information mentioned in Articles R. 225-81 and R. 225-83 of the French Commercial Code, up to and including the fifth day, preferably by email (Agiva25052023@inventivapharma.com) or at the head office by registered letter with acknowledgment of receipt. To this end, the shareholder shall indicate one's e-mail address in the request so that the Company can validly send him said documents in return. Bearer shareholders must provide proof of this status by sending a certificate of registration.

#### INVENTIVA

French *société anonyme* with a Board of Directors with a share capital of EUR 421,341.69 Registered office: 50, rue de Dijon, 21121 Daix, France 537 530 255 Trade and Companies Registry of Dijon

# REPORT OF THE BOARD OF DIRECTORS TO THE ORDINARY AND EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS OF MAY 25<sup>th</sup>, 2023

Madams and Sirs,

We have convened this combined general meeting to submit for your approval decisions that fall within the competence of the Ordinary General Meeting, on the one hand, and the Extraordinary General Meeting, on the other hand.

The purpose of this report is to present the draft resolutions submitted by the Board of Directors to the General Meeting. It is intended to present the main points of the draft resolutions, in accordance with the applicable law. It does not, therefore, claim to be exhaustive. Thus, it is essential that you read the text of the draft resolutions carefully before exercising your voting rights.

A summary of the Company's financial situation, activity and earnings during the past fiscal year, as well as the various information required by the applicable laws and regulations, is included in the universal registration document, which includes the 2022 annual financial report, available on the Company's website (<u>http://inventivapharma.com</u>), to which you are invited to refer.

You are hereby called to rule on the following agenda:

#### AGENDA

Reading of the reports of the Board of Directors and the Statutory Auditors ;

#### On an ordinary basis

- 1. Approval of the statutory financial statements for the financial year ended December 31<sup>st</sup>, 2022;
- 2. Approval of the consolidated financial statements for the financial year ended December 31<sup>st</sup>, 2022;
- 3. Appropriation of profit/loss for the financial year ended December 31<sup>st</sup>, 2022;
- 4. Approval of the expanses and charges referred to in Article 39(4) of the French General Tax Code;
- 5. Related-party agreements;
- Final approval of the fixed and variable compensation paid or awarded to Mr. Frédéric Cren in his capacity as Chairman of the Board of Directors and Chief Executive Officer for the financial year ended December 31<sup>st</sup>, 2022;
- 7. Final approval of the fixed and variable compensation paid or awarded to Mr. Pierre Broqua in his capacity as Deputy Chief Executive Officer for the financial year ended December 31<sup>st</sup>, 2022;
- 8. Approval of the information on corporate officers' compensation included in the corporate governance report and referred to in Article L.22-10-9 I. of the French Commercial Code;

- 9. Approval of the compensation policy for Mr. Frédéric Cren in his capacity as Chairman of the Board of Directors and Chief Executive Officer;
- 10. Approval of the compensation policy for Mr. Pierre Broqua in his capacity as Deputy Chief Executive Officer;
- 11. Approval of the compensation policy of the Company's directors;
- 12. Authorization granted to the Board of Directors to buyback the Company's shares;

#### On an extraordinary basis

13. Authorization to the Board of Directors to reduce the share capital by cancellation of shares;

### On an ordinary basis

14. Power of attorney to accomplish the formalities.

\*\*\*

We propose to examine hereafter each of the above proposals submitted for your approval.

# 1. APPROVAL OF BOTH THE STATUTORY AND CONSOLIDATED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED DECEMBER 31<sup>ST</sup>, 2022 - APPROPRIATION OF PROFIT/LOSS - REVIEW OF THE RELATED-PARTY AGREEMENTS (*FIRST TO FIFTH RESOLUTIONS*)

You are invited to refer to the management report of the Boards of Directors and to the reports (general and special) of the Statutory Auditors, including the universal registration document, which includes the 2022 annual financial report, both made available under the conditions provided by laws and regulations.

Concerning the state of business since the beginning of the current fiscal year, once again, you are invited to refer to the management report of the Boards of Directors.

# 2. COMPENSATION OF CORPORATE OFFICERS (*EX POST* VOTES) FOR THE FISCAL YEAR ENDED DECEMBER 31<sup>ST</sup>, 2022 (*SIXTH TO EIGTH RESOLUTIONS*)

The say on pay process regarding the compensation of corporate officers of listed companies implemented by the Act "Sapin II", as reformed by the ordinance No. 2019-1234 of November 27<sup>th</sup>, 2019 and the ordinance No. 2020-1142 of September 16<sup>th</sup>, 2020, provides that the annual ordinary general meeting is called to rule on:

- <u>an "individual" *ex post* vote</u>: on the fixed, variable and exceptional items making up the total compensation and benefits of any kind paid or granted in respect of the previous fiscal year by separate resolutions for the Chairman / Chief Executive Officer and the Deputy Chief Executive Officer, and
- <u>a "general" *ex post* vote</u>: on the information relating to the compensation of all corporate officers (including directors) mentioned in I of Article L. 22-10-9 of the French Commercial Code (general *ex post* vote) as presented in the corporate governance report.

You are therefore invited to refer (i) to section 3.5.1.5 of the corporate governance report included in the universal registration document, itself including the 2022 annual financial report, which presents the compensation paid or granted in respect of fiscal year 2022 to the Chairman / Chief Executive Officer and to the Deputy Chief Executive

Officer, and (ii) to section 3.5.1.6 of the same report for information on the compensation of corporate officers mentioned in section I of article L. 22-10-9 of the French Commercial Code.

Will be subject to your approval:

- <u>as part of the individual *ex post* vote</u>: the compensation paid or granted for the financial year 2022 to the Chairman / Chief Executive Officer and the Deputy Chief Executive Officer, as set out in 3.5.1.5 of the corporate governance report, and
- <u>in the context of the general *ex post* vote</u>: the information on the compensation of corporate officers mentioned in I of Article L. 22-10-9 of the French Commercial Code, as set out in 3.5.1.6 of the corporate governance report.

# 3. APPROVAL OF THE COMPENSATION POLICIES FOR THE CHAIRMAN / CHIEF EXECUTIVE OFFICER, DEPUTY CHIEF EXECUTIVE OFFICER, AS WELL AS DIRECTORS (*NINETH TO ELEVENTH RESOLUTIONS*)

The say on pay process regarding the compensation of corporate officers implemented by the Act "Sapin II", as reformed by the ordinance No. 2019-1234 of November 27<sup>th</sup>, 2019 and the ordinance No. 2020-1142 of September 16<sup>th</sup>, 2020, also provides that the annual ordinary general meeting is called to vote *ex ante*, on the compensation policy applicable to all corporate officers, including the directors.

The compensation policy, in its common aspects as well as in those aspects specific to each of the corporate officers and as determined by your Board of Directors, is described in sections 3.5.1.1 to 3.5.1.3 of the corporate governance report, included in the 2022 annual financial report, which is itself part of the universal registration document.

On March 17<sup>th</sup> 2023, the Board of Directors decided, on the proposal of the compensation and appointment Committee (*Comité des rémunérations et de nomination*), to adopt the terms of a compensation policy for the Chairman / Chief Executive Officer and the Deputy Chief Executive Officer for the financial year 2023, amended on two aspects compared to the previous policy submitted for your approval in 2022, whereas the terms of the compensation policy for directors remained unchanged.

These two amendments aim to complete the structure of the compensation of corporate officers by adding (i) a long-term incentive component that may take the form, subject to the conditions provided for in Article L. 225-197-1 of the French Commercial Code, of an allocation of performance shares or, failing that, an allocation of performance units, and (ii) the granting of a severance payment to them in certain cases of departure, in particular in the event of dismissal, non-renewal of their terms of office, or forced departure linked to a change of control.

The proposed amendments are in accordance with the evolution of the Company's shareholder structure. Mr. Frédéric Cren and Mr. Pierre Broqua, both founders and executive directors of the Company, hold respectively to date 13.3% and 9.2% of the Company's share capital, whereas their respective shareholdings were still 26.4% and 17.4% as at April 8<sup>th</sup>, 2019. Their progressive dilution, which is explained by the dynamics of strengthening the Company's equity to finance its development activities, has led the Board of Directors to further elaborate the structure of their compensation policy in order to maintain a high level of incentive for them while maintaining a strong convergence of interests between them and the Company's other shareholders.

Three resolutions will therefore be submitted for your approval, concerning the compensation policy as applied, respectively, to the Chairman / Chief Executive Officer, the Deputy Chief Executive Officer and the Directors.

# 4. AUTHORIZATION TO IMPLEMENT A SHARE REPURCHASE PLAN, AND CONCOMITANTLY TO AUTHORIZE THE BOARD TO REDUCE THE SHARE CAPITAL BY CANCELLING TREASURY SHARES (TWELFTH AND THIRTEENTH RESOLUTIONS)

We propose that you renew, in advance, the authorization granted to the Board of Directors, for a period of 18 months, by the ordinary and extraordinary general meeting of May 19<sup>th</sup>, 2022, in its 19<sup>th</sup> resolution, to implement a buyback program.

During previous fiscal years, this buyback program has been exclusively used within the framework of a liquidity agreement initially entered into with Oddo BHF (which was succeeded by an identical agreement with Kepler Cheuvreux), to meet the objective of allowing the liquidity of the Company's share through an investment services provider. The resolution that we submit to you aims at continuing the implementation of said liquidity agreement, within the limit of 10% of the shares composing the share capital, at any moment, the Board of Directors being able to lower this ceiling when implementing this resolution.

The maximum purchase price by share (excluding fees and commissions) would be set at EUR forty ( $\notin$ 40).We also submit to your approval the authorization to be granted to the Board of Director to cancel, if applicable, the treasury shares obtained while implementing the buyback program and to reduce the share capital correlatively.

Once again, this involves the anticipatory renewal of the authorization granted to the Board of Directors, for a period of 18 months, by the 20<sup>th</sup> resolution of the mixed general meeting of May 19<sup>th</sup>, 2022; to avoid having a period not covered by this authorization.

In all circumstances, the Company has currently no intention to cancel shares, its share repurchase plan being limited to the performance of the liquidity agreement.

\*\*\*

It is under these conditions that we ask you to vote on the resolutions proposed to you by your Board of Directors.

The Board of Directors

Important : Avant d'exercer votre choix, veuillez prendre connaissance des instructions situées au verso - Important : Before selecting please refer to instructions on reverse side Quelle que soit l'option choisie, noircir comme ceci au ou les cases correspondantes, dater et signer au bas du formulaire - Whichever option is used, shade box(es) like this , date and sign at the bottom of the form

U E DÉSIRE ASSISTER À CETTE ASSEMBLÉE et demande une carte d'admission : dater et signer au bas du formulaire / I WISH TO ATTEND THE SHAREHOLDER'S MEETING and request an admission card: date and sign at the bottom of the form

inventiva										ASSEMBLÉE GÉNÉRALE ORDINAIRE ET EXTRAORDINAIRE Jeudi 25 Mai 2023 à 14h00				CADRE RÉSERVÉ À LA SOCIÉTÉ - FOR COMPANY'S USE ONLY Identifiant - Account Vote simple Single vote Nominatif Registered Vote dauble				
50, rue de Dijon 21121 Daix										Hôtel Oceania Le Jura 14 avenue Foch, 21000 Dijon				shares	Porteur Bearer umber of voting	Do	ote double ouble vote	
Société anonyme au capital de 421 341,69 € 537 530 255 R.C.S DIJON																		
Cf. au verso (2) - See reverse (2) Je vote OUI à tous les projets de résolutions présentés ou agréés par le Conseil d'Administration ou le Directoire ou la Gérance, à l'EXCEPTION de ceux que je signale en noircissant comme ceci ■ l'une des cases "Non" ou "Abstention". / I vote YES all the draft resolutions approved by the Board							Conseil d oircissa ns appro	'Adminis nt commo	e ceci ∎ he Board	Sur les projets du résolutions non a vote en noircissa correspondant à On the draft reso approved, I cast shading the box choice.	agréés, je ant la case mon choix. <i>blutions not</i> <i>my vot</i> e by	t		Deprive the pour me représenter à l'Assemblée I HEREBY APPOINT: See reverse (4) to represent me at the above mentioned Meeting				
1 Non / No	2	3 □	<b>4</b> □	5 □	6 □	7 □	8	9 □	10 □	A Oui / Yes	B							
Abs.										Non / No Abs.		ATTENTION : Pour les titres au porteur, les présentes instructions doivent être transmises à votre banque.						
11	12	13	14	15	16	17	18	19	20	C	D	<b><u>CAUTION</u></b> : As for bearer shares, the present inst	tructions wil	be valid o	only if they are	directly	returned to your bank.	
Non / No 🔲 Abs. 🗖										Oui / Yes 🗌 Non / No 🗖 Abs. 🗖		Nom, prénom, adresse de l'actionnaire (les modifications de ces informations doivent être adressées à l'établissement concerné et ne peuvent être effectuées à l'aide de ce formulaire). Cf au verso (1) Surname, first name, address of the shareholder (Changes regarding this information have to be notified to relevant institution,						
21 Non / No 🗍 Abs. 🗆	22 □ □	23 □ □	24 □ □	25 □ □	26 □ □	27 □ □	28 □ □	29 □ □	30 □ □	E Oui / Yes 🗌 Non / No 🗌 Abs. 🗌	F    	no cna	anges can be i	nade using	this proxy form).	. See rev	verse (1)	
31 Non / No Abs.	32 □ □	33 □ □	34 □ □	35 □ □	36 □ □	37 □ □	38 □ □	39 □ □	<b>40</b> □	G Oui / Yes Non / No Abs.	H 0 0							
41 Non / No Abs.	42 □ □	43 □ □	44 □ □	45 □ □	<b>46</b> □ □	47 □ □	<b>48</b> □ □	49 □ □	50 □	J Oui / Yes Non / No Abs.	<b>K</b>							
Si des amendements ou des In case amendments or new - Je donne pouvoir au Prési - Je m'abstiens. / I abstain f - Je donne procuration [cf. au I appoint [see reverse (4)] I	resolutions a dent de l'as rom voting . verso renvo Mr, Mrs or Mi	re propose semblée g i (4)] à M., ss, Corpor	ed during th générale. / Mme ou M rate Name t	ne meeting, I appoint th Ille, Raison o vote on m	l vote <b>NO</b> ne Chairma Sociale po ny behalf	unless I indi an of the ge	cate anothe eneral mee	er choice by			respondante :							
Pour être pris en considérati To be considered, this comp à la banque / to the bank	leted form	mulaire d must be r 05/2023	oit parveni eturned no	ir au plus t	ard :							— Date & Signature —						0

#### CONDITIONS D'UTILISATION DU FORMULAIRE

(1) GENERALITES : Il s'agit d'un formulaire unique prévu par l'article R. 225-76 du Code de Commerce. QUELLE QUE SOIT L'OPTION CHOISIE : Le signataire est prié d'inscrire très exactement, dans la zone réservée à cet effet, ses nom (en majuscules), prénom usuel et adresse (les modifications de ces informations doivent être adressées à l'établissement concerné et ne peuvent être effectuées à l'aide de ce formulaire). Pour les personnes morales, le signataire doit renseigner ses nom, prénom et qualité. Si le signataire n'est pas l'actionnaire (exemple : Administrateur légal, Tuteur, etc.) il doit mentionner ses nom, prénom et la qualité	(3) POUVOIR AU PRÉSIDENT DE L'ASSEMBLÉE GÉNÉRALE <u>Article L. 225-106 du Code de Commerce (extrait)</u> : "Pour toute procuration d'un actionnaire sans indication de mandataire, le président de l'assemblée générale émet un vote favorable à l'adoption de projets de résolutions présentés ou agréés par le conseil d'administration ou le directoire, selon le cas, et un vote défavorable à l'adoption detous les autres projets de résolution. Pour émettre tout autre vote, l'actionnaire doit faire choix d'un mandataire qui accepte de voter dans le sens indiqué par le mandant".	Cette information porte notamment sur le fait que le mandataire ou, le cas échéant, la personne pour le compte de laquell agit : 1° Contrôle, au sens de l'article L 233-3, la société dont l'assemblée est appelée à se réunir ; 2° Est membre de l'organe de gestion, d'administration ou de surveillance de cette société ou d'une personne qui la contrôle sens de l'article L 233-3 ; 3° Est employé par cette société ou par une personne qui la contrôle au sens de l'article L 233-3 ; 4° Est contrôlé ou exerce l'une des fonctions mentionnées au 2° ou au 3° dans une personne ou une entité contrôlée par u personne qui contrôle la société, au sens de l'article L 233-3 ; Cette information est également délivrée lorsqu'il existe un lien familial entre le mandataire ou, le cas échéant, la persor pour le compte de laquelle il agit, et une personne physique placée dans l'une des situations énumérées aux 1° à 4°. Lorsqu'en cours de mandat, survient l'un des faits mentionnés aux alinéas précédents, le mandataire en informe sans délai s mandant. A défaut par ce dernier de confirmation expresse du mandat, celui-ci est caduc. La caducité du mandat est notifiée sans délai par le mandataire à la société. Les conditions d'application du présent article sont précisées par décret en Conseil d'Etat."		
en laquelle il signe le formulaire de vote. Le formulaire adressé pour une assemblée vaut pour les assemblées successives convoquées avec le même ordre du jour (article R. 225-77 alinés à du Code de commerce). Le texte des résolutions figure dans le dossier de convocation joint au présent formulaire (article R. 225-81 du Code de Commerce). Ne pas utiliser à la fois <i>u</i> le vote par correspondance » et « le donne pouvoir » (article R. 225-81 paragraphe 8 du Code de Commerce). Un guide méthodologique de traitement des assemblées générales, incluant une grille de lecture de ce formulaire de vote par correspondance est disponible sur le site de l'AFTI : <u>www.afti.asso.fr</u> La version française de ce document fait foi.	(4) POUVOIR À UNE PERSONNE DÉNOMMÉE (PERSONNE PHYSIQUE OU MORALE) <u>Article L. 225-106 du Code de Commerce (extrait) :</u> "I - Un actionnaire peut se faire représenter par un autre actionnaire, par son conjoint ou par le partenaire avec lequel il a conclu un pacte civil de solidarité. II - Le mandat ainsi que, le cas échéant, sa révocation sont écrits et communiqués à la société. Les conditions d'application du présent alinéa sont précisées par décret en Conseil d'Etat. III - Avant chaque réunion de l'assemblée générale des actionnaires, le président du conseil d'administration ou le directoire, selon le cas, peut organiser la consultation des actionnaires mentionnés à l'article L. 225-102 afin de leur permettre de désigner un ou plusieurs			
(2) VOTE PAR CORRESPONDANCE <u>Article L 225-107 du Code de Commerce (extrait)</u> : "Tout actionnaire peut voter par correspondance, au moyen d'un formulaire dont les mentions sont fixées par décret en Conseil d'Etat. Les dispositions contraires des statuts sont réputées non écrites. Pour le calcul du quorum, il n'est tenu compte que des formulaires qui ont été reçus par la société avant la réunion de l'assemblée, dans les conditions de délais fixées par décret en Conseil d'Etat. Les formulaires ne donnant aucun sens de vote ou exprimant une abstention ne sont pas considérés comme des votes exprimés".	mandataires pour les représenter à l'assemblée générale conformément aux dispositions du présent article. Cette consultation est obligatoire lorsque, les statuts ayant été modifiés en application de l'article L. 225-23 ou de l'article L. 225-71, l'assemblée générale ordinaire doit nommer au conseil d'administration ou au conseil de surveillance, selon le cas, un ou des salariés actionnaires ou membres des conseils de surveillance des fonds communs de placement d'entreprise détenant des actions de la société. Cette consultation est également obligatoire lorsque l'assemblée générale extraordinaire doit se prononcer sur une modification des statuts en application de l'article L. 225-23 ou de l'article L. 225-71. Les clauses contraires aux dispositions des alinéas précédents sont réputées non écrites."	Article L. 22-10-41 du Code de commerce : "Toute personne qui procède à une sollicitation active de mandats, en proposant directement ou indirectement à un ou plusieurs actionnaires, sous quelque forme et par quelque moyen que ce soit, de recevoir procuration pour les représenter à l'assemblée d'une société mentionnée au premier alinéa de l'article L. 22-10-39, rend publique sa politique de vote. Elle peut également rendre publiques ses intentions de vote, un vote conforme aux intentions de vote ainsi rendues publiques. Les conditions d'application du présent article sont précisées par décret en Conseil d'Etat."		
La majorité requise pour l'adoption des décisions est déterminée en fonction des voix exprimées par les attoinnaires présents ou représentés. Les voix exprimées ne comprennent pas celles attachées aux actions pour lesquelles l'actionnaire n'a pas pris part au vote, s'est abstenu ou a voté blanc ou nul. (articles L. 225-96 et L. 225-98 du Code de Commerce et, s'agissant des sociétés ayant adopté le statut de la société européenne, et articles 57 et 58 du Règlement du Conseil (CE) N°2157/2001 relatif au statut de la société européenne). Si vous vote par correspondance : vous devez obligatoirement noircir la case "Je vote par correspondance" au recto. 1 - il vous est demandé pour chaque résolution en noircissant individuellement les cases correspondantes : - soit de voter "Nou" (vote exprimé par défaut pour les projets de résolutions présentés ou agréés, en l'absence d'un autre choix); - soit de voter "Non":	Article L. 22-10-39 du Code de Commerce : "Outre les personnes mentionnées au I de l'article L. 225-106, un actionnaire peut se faire représenter par toute autre personne physique ou morale de son choix lorsque les actions de la société sont admises aux négociations sur un marché réglementé ou sur un système multilatéral de négociation soumis aux dispositions du II de l'article L. 433-3 du code monétaire et financier dans les conditions prévues par le règlement général de l'Autorité des marchés financiers, figurant sur une liste arrêtée par l'autorité dans des conditions fixées par son règlement général, à condition dans cette seconde hypothèse, que les statuts le prévoient. Les clauses contraires aux dispositions du précédent alinéa sont réputées non écrites."	Article L. 22-10-42 du Code de commerce : "Le tribunal de commerce dans le ressort d'uquel la société a son siège social peut, à la demande du mandant et pour une durée qui ne saurait excéder trois ans, priver le mandataire du droit de participer en cette qualité à toute assemblée de la société concernée en cas de non-respect de l'obligation d'information prévue aux troisième à septième alinéas de l'article L. 22-10-40 ou des dispositions de l'article L. 22-10-41. Le tribunal peut décide la publication de cette décision aux frais du mandataire. Le tribunal peut prononcer les mêmes sanctions à l'égard du mandataire sur demande de la société en cas de non-respect des dispositions de l'article L. 22-10-41.		
- sont de vous "Abstenir" en noircissant individuellement les cases correspondantes. 2 - Pour le cas où des amendements aux résolutions présentées ou des résolutions nouvelles seraient déposées lors de l'assemblée, il vous est demandé d'opter entre vote contre (vote exprimé par défaut en l'absence d'un autre choix), pouvoir au président de l'assemblée générale, abstention ou pouvoir à personne démommé en noircissant la case correspondant à votre choix.	<u>Article L.22-10-40 du Code de Commerce :</u> "Lorsque, dans les cas prévus au premier alinéa du I de l'article L. 22-10-39, l'actionnaire se fait représenter par une personne autre que son conjoint ou le partenaire avec lequel il a conclu un pacte civil de solidarité, il est informé par son mandataire de tout fait lui permettant de mesurer le risque que ce dernier poursuive un intérêt autre que le sien.			

Les informations à caractère personnel recueillies dans le cadre du présent document sont nécessaires à l'exécution de vos instructions de vote. Vous disposez d'un certain nombre de droits concernant vos données (accès, rectification, etc.). Ces droits peuvent être exercés auprès de votre teneur de compte aux coordonnées indiquées par ce dernier.

#### FORM TERMS AND CONDITIONS

(1) GENERAL INFORMATION: This is the sole form pursuant to article R. 225-76 du Code de Commerce WHICHEVER OPTION IS USED: The signatory should write his/her exact name and address in capital letters in the space provided e.g. a legal guardian: (Change regarding this information have to be notified to relevant institution, no change can be made using this proxy form). If the signatory is a legal entity, the signatory should indicate his/her full name and the capacity in which he is entitled to sign on the legal entity's behalf. If the signatory is not the shareholder (e.g. a legal guardian), please specify your full name and the capacity in which you are signing the proxy.	<ul> <li>(3) PROXY TO THE CHAIRMAN OF THE GENERAL MEETING         <u>Article L. 225-106 du Code de Commerce (extract):</u>         "In case of any power of representation given by a shareholder without naming a proxy, the chairman of the general         meeting shall issue a vote in favor of adopting a draft resolutions submitted or approved by the Board of Directors or the         Management Board, as the case may be, and a vote against adopting any other draft resolutions. Toissue any other vote,         the shareholder must appoint a proxy who agrees to vote in the manner indicated by his principal."     </li> <li>(4) PROXY TO A MENTIONED PERSON (INDIVIDUAL OR LEGAL ENTITY)     </li> </ul>	This information relates in particular to the event that the proxy or, as the case may be, the person on behalf of whom it acts: 1° Controls, within the meaning of article L. 233-3, the company whose general meeting has to meet; 2° Is member of the management board, administration or supervisory board of the company or a person which controls it within the meaning of the article L. 233-3; 3° Is employed by the company or a person which controls it within the meaning of article L. 233-3; 4° Is controlled or carries out one of the functions mentioned with the 2° or the 3° in a person or an entity controlled by a person who controls the company, within the meaning of the article L. 233-3.				
The form sent for one meeting will be valid for all meetings subsequently convened with the same agenda (art. R. 225-77 alinéa 3 du Code de Commerce). The text of the resolutions is in the notification of the meeting which is sent with this proxy (article R. 225-81 du Code de Commerce). Please do not use both "1 vote by post" and "1 hereby appoint" (article R. 225-81 du Code de Commerce). A guide relating to the general meetings processing, including an interpretation grid of this proxy form, is available on the AFTI website at: <u>www.afti.asso.fr</u> <b>The French version of this document governs; The English translation is for convenience only.</b>	Article L. 225-106 du Code de Commerce (extract): "I - A shareholder may be represented by another shareholder, by his or her spouse, or by his or her partner who he or she has entered into a civil union with. II - The proxy as well as its dismissal, as the case may be, must be written and made known to the company. A Conseil d'Etat decree specifies the implementation of the present paragraph. III - Before every general meeting, the chairman of the board of directors or the management board, as the case may be, may organise a consultation with the shareholders mentioned in article L. 225-102 to enable them to appoint one or more proxies to represent them at the meeting in accordance with the provisions of this Article.	This information is also delivered when a family tie exits between the proxy or, as the case may be, the person on behalf of whom it acts, and a natural person placed in one of the situations enumerated from 1° to 4° above. When during the proxy, one of the events mentioned in the preceding subparagraphs occurs, the proxy informs without delay his constituent. Failing by the latter to confirm explicitly the proxy, this one is null and void. The termination of the proxy is notified without delay by the proxy to the company. The conditions of application of this article are determined by a Conseil d'Etat decree."				
(2) POSTAL VOTING FORM <u>Article L. 225-107 du Code de Commerce (extract):</u> "Any shareholder may vote by post, using a form the wording of which shall be fixed by a decree approved by the Conseil d'Etat. Any provisions to the contrary contained in the memorandum and articles of association shall be deemed non- existent. When calculating the quorum, only forms received by the company before the meeting shall be taken into account, on conditions to be laid down by a decree approved by the Conseil d'Etat. The forms giving no voting direction or indicating abstention shall not be considered as votes cast." The majority required for the adoption of the general meeting's decisions shall be determined on the basis of the votes cast by the shareholder present or represented. The votes cast shall not include votes attaching to shares in respect of which the shareholder has not taken part in the vote or has abstrained or has returned a blank or spoilt ballot paper (articles L. 225-96 and L. 225-98 du Code de Commerce and, for the companies which have adopted the statute of European company, articles 57 and 58 of the Council Regulation (EC) n°2157/2001 on the statute for a European company). If you wish to use the postal voting form, you have to shade the box on the front of the document: "I vote by post". 1 - In such event, please comply for each resolution the following instructions by shading boxes of your choice: - either vote "Yes" (in absence of choice, vote expressed by default for the approved draft resolutions).	Such a consultation shall be obligatory where, following the amendment of the memorandum and articles of association pursuant to article L. 225-23 or article L. 225-71, the ordinary general meeting is required to appoint to the board of directors or the supervisory board, as the case may be, one or more shareholder employees or members of the supervisory board and the company investment funds that holds company's shares. Such a consultation shall also be obligatory where a special shareholders' meeting is required to take a decision on an amendment to the memorandum and articles of association pursuant to article L. 225-23 or article L. 225-71. Any clauses that conflict with the provisions of the preceding sub-paragraphs shall be deemed non-existent." Article L. 22-10-39 du Code de commerce: "In addition to the persons mentioned in I of article L. 225-106, a shareholder may be represented by any other natural or legal person of his choice where the shares of the company are admitted to trading on a regulated market or on a multilateral trading facility subject to the provisions of the Autorité des marchés financiers, appearing on a list drawn up by the latter under conditions laid down in its General Regulations, provided that in this second case, as provided for in the articles of association. Clauses contrary to the provisions of the preceding paragraph shall be deemed unwritten."	Article L. 22-10-41 du Code de commerce:         "Any person who proceeds to an active request of proxy, while proposing directly or indirectly to one or more shareholders, under any form and by any means, to receive proxy to represent them at the general meeting of a company mentioned in the first paragraph of the article L. 22-10-39, shall release its voting policy.         It can also release its voting intentions on the draft resolutions submitted to the general meeting, It exercises then, for any proxy received without voting instructions, a vote in conformity with the released voting intentions. The conditions of application of this article are determined by a Conseil d'Etat decree."         Article L. 22-10-42 du Code de commerce:         "The commercial court of which the company's head office falls under can, at the request of the constituent and for a duration which cannot exceed three years, deprive the proxy of the right to take part in this capacity to any general meeting of the relevant company in the event of non-compliance with mandatory information envisaged from the third to seventh paragraphs of article L. 22-10-40 or with the proxy.         The court can impose the same sanctions towards the proxy on request of the company in the event of non-compliance of the mandatory information.				
<ul> <li>or vote "No",</li> <li>or vote "Abstention" by shading boxes of your choice.</li> <li>In case of amendments or new resolutions during the general meeting, you are requested to choose between vote "No" (vote expressed by default in absence of choice), proxy to the chairman of the general meeting, "Abstention" or proxy to a mentioned person individual or legal entity by shading the appropriate box.</li> </ul>	Article L. 22-10-40 du Code de commerce: "When, in the events envisaged by the first paragraph of the article L. 22-10-39, the shareholder is represented by a person other than his or her spouse or his or her partner who he or she has entered into a civil union with, he or she is informed by the proxy of any event enabling him or her to measure the risk that the latter pursue an interest other than his or hers.					
Personal data included in this form are necessary for the execution of your voting instructions. You have certain minimum rights regarding your data (access, correction). These rights may be exercised using the contact details provided by your custodian.						

#### PARTICIPATE AND VOTE AT THE GENERAL MEETING OF MAY 25th, 2023

# A. PRELIMINARY FORMALITIES TO BE CARRIED OUT TO PARTICIPATE IN THE GENERAL MEETING

Each shareholder, no matter the number of shares possessed and the manner they are held, can participate to the General Meeting, subject to the formalities set out below.

Shareholders shall provide proof of the registration of their shares in their name or that of the intermediary registered on their behalf no later than Tuesday, May 23<sup>rd</sup>, 2023 (i.e. before the second business day preceding the general meeting at midnight, Paris time), either in the registered accounts held by the Company, or in the bearer shares accounts held by the authorized intermediary.

You may prove your status as a shareholder as follows:

- <u>for registered shareholders</u>: your status as a shareholder is evidenced only by the registration of your shares in a registered account no later than zero hour Paris time on Tuesday, May 23<sup>rd</sup>, 2023;
- <u>for holders of bearer shares</u>: you must contact your financial intermediary, indicating that you wish to
  participate in the General Meeting, and ask this intermediary to draw up a certificate of participation
  noting the registration or book entry of your shares no later than zero hour, Paris time, on Tuesday, May
  23<sup>rd</sup>, 2023.

#### **B. MODALITIES OF ATTENDANCE TO THE GENERAL MEETING**

To participate in the General Meeting, shareholders, whether registered or bearer, may (1) attend in person or (2) vote by e-mail or be represented by giving a proxy to the Chairman of the Meeting, to their spouse, to the person with whom a civil solidarity pact has been concluded, to another shareholder or to any other natural person or legal entity of their choice in accordance with the conditions set forth in Articles L.225-106 and L.22-10-39 of the French Commercial Code, or (3) by Internet.

#### 1. TO ATTEND TO THE COMPANY GENERAL MEETING

The shareholders wishing to personally attend the General Meeting must request an admission card as soon as possible to receive the card in a timely manner:

#### For registered shareholders:

- either by returning the single form duly completed and signed using the pre-paid reply envelope enclosed with the invitation received by post mail to the *Services des Assemblées* (SGSS/SBO/CIS/ISS/GMS) of Société Générale, CS 30812, 44308 Nantes Cedex; or
- by logging in on the website www.sharinbox.societegenerale.com using their usual access codes or their login email (if they have already activated their Sharinbox by SG Markets account), together with the password they already have. The password to connect to the site was sent to them by post when they first contacted Société Générale Securities Services. It can be re-sent by clicking on "Obtain your codes" on the home page of the website. Once connected, they should follow the procedure described on the screen to access the VOTACCESS platform and request

their admission card; the registered shareholder who would not have received her admission card may spontaneously attend the General Meeting with an identification document.

- For holders of bearer shares:
  - either by asking the authorized intermediary managing their share-accounts to send them an admission card. Should the admission card not be received by Tuesday, May 23<sup>rd</sup>, 2023, zero hour, Paris time, the shareholder shall ask the authorized intermediary managing their share-accounts to issue a certificate of participation in order to prove their status as shareholders; or
  - by logging in on the Internet portal of their account holder with their usual access codes. The shareholder will then have to click on the icon that will appear on the line corresponding to their Inventiva shares to access the Votaccess website and follow the procedure described on the screen. Only the bearer shareholder whose account holder has subscribed to the Votaccess website will be able to fulfil their request for admission card via Internet.

On the day of the General Meeting, each shareholder will have to prove her or his quality during the registration process (please have a valid State-issued identification document with a photograph).

The General Meeting will start at 2 p.m. (sharp). In order to facilitate the smooth running of the Meeting, we recommend to shareholders wishing to attend it in person to:

- come to the reception desk at 1:30 p.m. to sign the attendance sheet with an identity card, an admission card or a certificate of participation if you are a bearer shareholder who does not have an admission card;
- arrive before the time set for the start of the General Meeting. After this time, the access to the meeting room with voting rights cannot be guaranteed.

# 2. VOTE AT THE GENERAL MEETING BY MAIL USING THE VOTING FORM

### 2.1 You hold registered Inventiva shares

2.1.1 You have received a voting form at your address

YOU GIVE PROXY TO THE PRESIDENT	YOU GIVE PROXY TO AN INDIVIDUAL OR LEGAL ENTITY OF YOUR CHOSING	YOU VOTE REMOTELY
Check the second box of the form;	Check the third box of the form;	Check the first box of the form;
- date and sign at the bottom of	- specify the identity and	- specify your vote;
the form.	complete contact information	- date and sign at the bottom of
	of the person who will	the form.
Send your request by postal mail	represent you;	
directly to the Services des	- specify your last name, first	You want to vote "in favor" of each
Assemblées of Société Générale, 32,	name and address or check	resolution: do not blacken any box.
rue du Champs de Tir, CS 30812,	them if they are prefilled;	You want to vote "against" a
44308 Nantes Cedex 3, at the latest	- date and sign at the bottom of	resolution or to "abstain": blacken
three days before the meeting,	the form.	the box "no" or "abs" that
that is Monday, May 22 <sup>th</sup> , 2023.		corresponds to the number of the
	Send your request by postal mail	resolution concerned.
Your votes will be added to those of	directly to the Services des	Send your request by postal mail
the President.	Assemblées of Société Générale,	directly to the Services des

YOU GIVE PROXY TO THE	YOU GIVE PROXY TO AN	YOU VOTE REMOTELY
PRESIDENT	INDIVIDUAL OR LEGAL	
	ENTITY OF YOUR CHOSING	
	32, rue du Champs de Tir, CS	Assemblées of Société Générale, 32,
✓ You have voted.	30812, 44308 Nantes Cedex 3, at	rue du Champs de Tir, CS 30812,
	the latest three days before the	44308 Nantes Cedex 3, at the latest
	meeting, that is Monday, May	three days before the meeting,
	22 <sup>th</sup> , 2023.	that is Monday, May 22 <sup>th</sup> , 2023.
	✓ You gave proxy.	✓ You have voted.

# 2.1.2 You did not receive a voting form at your address


You can get copy of the remote voting form on Inventiva's website (<u>www.inventivapharma.com</u>, in the Investors' Section (*Espaces Investisseurs*), subsection documentation - General Meetings). You just have to print it, complete it and return it to the *Services des Assemblées* of Société Générale, 32, rue du Champs de Tir, CS 30812, 44308 Nantes Cedex 3 as specified in section 2.1.1 above.

You can, in any case, send a written request on plain paper to Inventiva to request a remote voting form.

# 2.2 You hold Inventiva bearer shares

You need to reach out to your financial intermediary holding your securities account in which you Inventiva shares are registered to request a remote voting form. Each demand must be addressed by the financial intermediary to the *Services des Assemblées* of Société Générale, 32, rue du Champs de Tir, CS 30812, 44308 Nantes Cedex 3 at the latest six days before the date of the General Meeting (Article R. 225-75 of the French Commercial Code): complete the form as specified in section 2.1.1 above and return the form duly completed to your financial intermediary which will forward it to the *Services des Assemblées* of Société Générale, 32, rue du Champs de Tir, CS 30812, 44308 Nantes Cedex 3. Your financial intermediary will add to your request a certificate of ownership of shares dated at least 2 business days before the date of the General Meeting. The form need be received by the *Services des Assemblées* of Société Générale at least 3 calendar days before the General Meeting (i.e. on Monday, May 22<sup>th</sup>, 2023).

### 2.3 How to fill your voting form



# 3. VOTING OR GIVING PROXY AT THE GENERAL MEETING VIA INTERNET

Inventiva provides its shareholders with the website Votaccess dedicated to Internet voting prior to the General Meeting. This site allows each shareholder to cast his or her vote by telecommunication means, prior to the General Meeting, under the conditions defined below. The secured plateform *Votaccess*, allowing to vote on the resolutions or to give proxy by Internet, will open as of Friday, May 5<sup>th</sup>, 2023 at 9 a.m., Paris time, until Wednesday May 24<sup>th</sup>, 2023, at 3 p.m, Paris time.

Shareholder may also name or revoke a proxy by Internet, under the conditions set out below, prior to the General Meeting, on the *Votaccess* website or by e-mail at the following address: <u>Agiva25052023@inventivapharma.com</u>.

### 3.1 You hold registered Inventiva shares

Login the *Votaccess* website via the website for the management of your registered shares (*www.sharinbox.societegenerale.com*), with your access code and password:

- Access code: it appears at the top of your statements;
- Password: it has been sent to you by mail when you first reached out to Société Général Securities Services. If you have lost or forgotten your password, go to the home page of the site and click on "Get your codes". You will then have to click on the name of the General Meeting under the heading "Current Operations" of the home page. You will then need to select the transaction, follow the instructions for the purpose of voting or giving a proxy. Click on "Vote" to access the voting site.

The possibility to vote via Internet before the General Meeting will end the day before the meeting, that is Wednesday, May 24<sup>th</sup>, 2023 at 3 p.m., Paris time. However, to avoid a potential saturation of the website *Votaccess*, the shareholders are advised not to wait until the day before the General Meeting to vote.

You also may give or revoke a proxy by sending an e-mail with an electronic signature, obtained by you from a third party certifier duly authorized pursuant to legal and regulatory provisions in force, to the electronic address

<u>Agiva25052023@inventivapharma.com</u> specifying, as for pure registered shareholders, your name, first name, address and your Société Générale access code (information available at the top left of their account statement), or, as for administered registered shareholders, your access code with your authorized intermediary, as well as the name, first name and address of the appointed or revoked agent. In order for the duly signed and completed appointments or revocations of proxy to be validly taken into account, they must reach the Company no later than Monday, May 22<sup>th</sup>, 2023, as regards notification made by electronic means.

For any request, SGSS is available to shareholders from 9:30 a.m. to 6:00 p.m. on the following telephone number: +33 (0)2 51 85 67 89.

#### 3.2 You hold Inventiva bearer shares

You want to vote or give a proxy via Internet, prior to the General Meeting: log in, with your usual access code, on your bank's portal dedicated to the management of your shares. To access the *Votaccess* website and vote, you just have to click on the icon that will appear on the line corresponding to your Inventiva shares.

It is specified that only holders of bearer shares whose account-holding institution has subscribed to Votaccess will be able to access the website. If your account-holding institution is not connected to Votaccess, the notice of appointment or revocation of a proxy can still me effectuated by email, pursuant to Article R. 225-79 of the French Commercial Code according to the following procedures: by sending an email to Agiva25052023@inventivapharma.com. This email must contain the following information: name of the Company, last name, first name, address, bank references of the principal, as well as the last name, first name and, if possible, address of the agent. You must ask your authorized intermediary to send a written confirmation to Services des Assemblées of Société Générale, 32, rue du Champs de Tir, CS 30812, 44308 Nantes Cedex 3. In order for appointments or revocations of proxies to be validly taken into account, the confirmations must be received at the latest the day before the General Meeting at 3 p.m. (Paris time). In order for the duly signed and completed appointments or revocations of proxy to be validly taken into account, they must reach the Company no later than Monday, May 22th, 2023, as regards notification made by electronic means.

## **INVENTIVA**

#### **GENERAL MEETING OF MAY 25, 2023**

#### **REQUEST FOR ATTACHMENTS**

I, the undersigned:		
Last Name:		
First Name:		
Address:		 
Owner of	registered shares*,	
And/or of	bearer shares,	

of the Company **INVENTIVA**, whose registered office is located: 50, rue de Dijon, DAIX (21121), France, registered with the Commerce and Companies Register of Dijon under the No. 537 530 255 RCS Dijon,

request the sending of the documents and information related to the General Meeting of May 25, 2023, as they are identified in Article R.225-83 of the French Commercial Code, with the exception of those attached to the single voting form.

Made in \_\_\_\_\_ on \_\_ / \_\_ / 2023

Signature

\* In accordance with Article R.225-88 paragraph 3 of the French Commercial Code, the shareholders owning registered shares can, upon single request, obtain the sending by the Company of the documents and information identified in Articles R.225-81 and R.225-83 of the French Commercial Code, for each subsequent General Meeting. Should the shareholder wish to benefit from this option, this must be mentioned on the present request.